ANN ROY: Open Payments
NPI 1922675537 · SUGAR LAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,862 in 68 payments from 13 companies in 2025. Trend: 2023 $48 · 2024 $1,137 · 2025 $1,862
Food & beverage: $1,862
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $570 |
| Novo Nordisk Inc | 10 | $287 |
| Bayer Healthcare Pharmaceuticals Inc. | 11 | $209 |
| Merck Sharp & Dohme LLC | 8 | $164 |
| Lilly USA, LLC | 4 | $140 |
| Sumitomo Pharma America, Inc. | 6 | $129 |
| Corcept Therapeutics | 6 | $119 |
| GlaxoSmithKline, LLC. | 4 | $105 |
| Xeris Pharmaceuticals, Inc. | 3 | $53 |
| CeQur Corporation | 1 | $35 |
Products named: Ozempic, BREZTRI, FARXIGA, Kerendia, JARDIANCE, GEMTESA, VERQUVO, Korlym.
Industry payments across TX — which companies pay providers there.
